Haleon PLC

HLN

Equity

ISIN GB00BMX86B70 / Valor 119556867

LSE London Stock Exchange, SETS (2024-12-24)

GBP 3.82+0.47%

Haleon PLC
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Haleon PLC is a world-leading consumer health company focused on delivering better everyday health with humanity. The company's leading brands, including Sensodyne, Polident, and parodontax, are trusted by millions of consumers globally. With a strong portfolio of brands, Haleon is well-positioned to play a vital role in the growing consumer health sector. The company is committed to making everyday oral health better for people and the planet, emphasizing science, innovation, and human understanding in its products and services.

Summarized from source with an LLMView SourceSector: Business Services

Organic Revenue Growth

In the third quarter of 2024, Haleon PLC reported a strong organic revenue growth of 6.1%, driven by a balanced increase in both price and volume/mix. The company's Power Brands, including Sensodyne, parodontax, Advil, and Theraflu, contributed significantly to this growth. Despite a reported revenue decline of 0.6%, the company remains on track to achieve its full-year organic revenue growth guidance of 4-6% for 2024.

Operating Profit Performance

Haleon PLC achieved a 7.4% organic operating profit growth in Q3 2024, supported by gross margin expansion and cost efficiencies. The adjusted operating profit margin increased to 23.0%, reflecting a 30 basis points organic improvement. The company reported an operating profit of £705 million, marking a 20.7% increase, which includes a £121 million gain from the divestment of its Nicotine Replacement Therapy business outside the US.

Capital Allocation and Shareholder Returns

During the third quarter of 2024, Haleon PLC raised approximately £0.8 billion through the divestment of non-core brands, including the Nicotine Replacement Therapy business and ChapStick. The company also returned over £1 billion to shareholders through share buybacks and dividends. Additionally, Haleon agreed to acquire an additional 33% equity interest in its China joint venture, increasing its participation to 88%.

Category and Regional Performance

Haleon PLC's Oral Health category saw an 8.2% organic revenue growth in Q3 2024, driven by strong performances from Sensodyne and parodontax. The company experienced growth across all regions, with notable improvements in North America and strong growth in China. The Vitamins, Minerals, and Supplements category also grew by 3.7%, with Caltrate performing well in China.

2024 Outlook

For the full year 2024, Haleon PLC expects to achieve an organic revenue growth of 4-6% and high-single-digit organic operating profit growth. The company anticipates a net interest expense of approximately £320 million and an adjusted effective tax rate of 24-25%. Despite the impact of foreign exchange and mergers and acquisitions, Haleon remains confident in delivering its financial guidance for the year.

Summarized from source with an LLMView Source

Key figures

18.9%1Y

%3Y

%5Y

Performance

16.7%1Y

21.1%3Y

21.1%5Y

Volatility